Curocell Inc. (KOSDAQ:372320)

South Korea flag South Korea · Delayed Price · Currency is KRW
46,750
-950 (-1.99%)
At close: Jan 16, 2026
65.78%
Market Cap666.07B
Revenue (ttm)n/a
Net Income (ttm)-39.26B
Shares Out14.43M
EPS (ttm)-2,755.02
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume107,663
Average Volume141,714
Open46,850
Previous Close47,700
Day's Range45,650 - 47,400
52-Week Range23,750 - 58,100
Beta1.51
RSI47.02
Earnings DateMar 13, 2026

About Curocell

Curocell Inc. develops CAR-T cell therapy for the treatment of cancer. It focuses on the development of CD19 CAR-T for the treatment of lymphoma; and BCMA CAR-T for the treatment of multiple myeloma. The company was incorporated in 2016 and is based in Daejeon, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 372320
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.